



Orion Operations - Global and Local

Liisa Hurme
SVP, Global Operations
Chair of Fermion Board of Directors


Disclaimer

This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company's future activities and performance. They include statements about future strategies and anticipated benefits of these strategies.

These statements are subject to risks and uncertainties. Actual results may differ substantially from those stated in any forward-looking statement. This is due to a number of factors, including the possibility that Orion may decide not to implement these strategies and the possibility that the anticipated benefits of implemented strategies are not achieved. Orion assumes no obligation to update or revise any information included in this presentation.


All the figures in this presentation have been rounded, which is why the total sums of individual figures may differ from the total sums shown.

Orion's operations mainly in Finland - Supply Chains Global



*API = Active Pharmaceutical Ingredient


Degree of domestic production higher than average in Orion products - but dependent on global raw material flows



Fermion has an important strategic role within Orion Group

Develops, manufactures and sells active pharmaceutical ingredients (APIs)

Markets drug product contract manufacturing services of Orion



APIs to all Orion proprietary products and a number of generic products



Focus on APIs that are challenging to manufacture - special expertise in high potency APIs



Generic APIs to other pharma companies



Global market leader in some products




API contract development and manufacturing



~230 customers, ~30 products

ESG focus areas





Orion Corporation Capital Markets Day